Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
Certara2025 年 9 月 22 日
Certara Announces Fall 2025 Certainty Circuit in EMEA, APAC
Join Certara's Fall 2025 Certainty Circuit in EMEA & APAC to explore AI-enabled biosimulation insights,…
Certara2025 年 9 月 17 日
Streamline Table Creation with AI-Specialized for Regulatory Writers
Learn how AI-powered CoAuthor™ transforms table creation for regulatory and medical writers. Watch our free…
Certara2025 年 8 月 27 日
Certara Integral: The Master Data Repository Powering Efficient and Collaborative PK/PD Workflows
Charles River improved its global pharmacokinetics workflows by adopting Certara’s Integral as a central data…
Certara2025 年 8 月 27 日
Differences between eCTD 4.0 and eCTD 3.2.2 Submissions – What You Need to Know
Access our on-demand webinar to explore the key differences between eCTD 4.0 and eCTD 3.2.2.…
Certara2025 年 8 月 11 日
Certara Reports Second Quarter 2025 Financial Results
RADNOR, PA— 2025 年 8 月 6 日-- Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development,…
Certara2025 年 8 月 6 日
De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator
Watch the on-demand presentation covering how the DIDB® Concomitant Meds Navigator empowers clinical development teams…
Certara2025 年 8 月 5 日
Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials
GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…
Certara2025 年 7 月 31 日
